Table 1.

Multivariable Cox proportional cause-specific hazards models for association between permissive and nonpermissive HLA-DPB1 mismatches and aGVHD, NRM, and disease relapse using different TCE stratification strategies

End pointTCE (standard)TCE core/noncoreTCE core/noncore (directional)
DPB1 matchingHR (99% CI)P valueDPB1 matchingHR (99% CI)P valueDPB1 matchingHR (99% CI)P value
aGVHD 2-4 Match  Match  Match  
Permissive 1.23 (1.07-1.41) <.001 Core permissive 1.05 (0.88-1.24) .5 Core permissive 1.05 (0.88-1.24) .5 
Noncore permissive 1.36 (1.16-1.60) <.0001 Noncore permissive HVG 1.11 (0.88-1.39) .3 
Noncore permissive GVH 1.55 (1.28-1.86) <.0001 
Nonpermissive 1.40 (1.21-1.61) <.0001 Nonpermissive 1.39 (1.21-1.61) <.0001 Nonpermissive HVG 1.28 (1.05-1.55) .001 
Nonpermissive GVH 1.46 (1.25-1.71) <.0001 
aGVHD 3-4 Match  Match  Match  
Permissive 1.25 (0.99-1.59) .014 Core permissive 1.11 (0.83-1.48) .4 Core permissive 1.11 (0.83-1.48) .4 
Noncore permissive 1.36 (1.03-1.80) .005 Noncore permissive HVG 1.27 (0.87-1.86) .1 
Noncore permissive GVH 1.42 (1.03-1.96) .005 
Nonpermissive 1.48 (1.16-1.90) <.0001 Nonpermissive 1.48 (1.16-1.90) <.0001 Nonpermissive HVG 1.52 (1.11-2.09) <.001 
Nonpermissive GVH 1.46 (1.11-1.92) <.001 
NRM Match  Match  Match  
Permissive 1.12 (0.94-1.33) .09 Core permissive 1.09 (0.89-1.34) .3 Core permissive 1.09 (0.89-1.34) .3 
Noncore permissive 1.11 (0.90-1.37) .2 Noncore permissive HVG 1.21 (0.91-1.59) .08 
Noncore permissive GVH 1.05 (0.82-1.35) .6 
Nonpermissive 1.26 (1.05-1.50) .001 Nonpermissive 1.26 (1.05-1.50) .001 Nonpermissive HVG 1.17 (0.92-1.48) .09 
Nonpermissive GVH 1.31 (1.07-1.59) <.001 
Relapse Match  Match  Match  
Permissive 0.87 (0.77-0.99) .007 Core permissive 0.93 (0.80-1.08) .2 Core permissive 0.93 (0.80-1.08) .2 
Noncore permissive 0.83 (0.71-0.97) .003 Noncore permissive HVG 0.93 (0.75-1.15) .4 
Noncore permissive GVH 0.77 (0.63-0.94) <.001 
Nonpermissive 0.77 (0.67-0.88) <.0001 Nonpermissive 0.77 (0.67-0.88) <.0001 Nonpermissive HVG 0.83 (0.69-1.00) .010 
Nonpermissive GVH 0.73 (0.63-0.86) <.0001 
End pointTCE (standard)TCE core/noncoreTCE core/noncore (directional)
DPB1 matchingHR (99% CI)P valueDPB1 matchingHR (99% CI)P valueDPB1 matchingHR (99% CI)P value
aGVHD 2-4 Match  Match  Match  
Permissive 1.23 (1.07-1.41) <.001 Core permissive 1.05 (0.88-1.24) .5 Core permissive 1.05 (0.88-1.24) .5 
Noncore permissive 1.36 (1.16-1.60) <.0001 Noncore permissive HVG 1.11 (0.88-1.39) .3 
Noncore permissive GVH 1.55 (1.28-1.86) <.0001 
Nonpermissive 1.40 (1.21-1.61) <.0001 Nonpermissive 1.39 (1.21-1.61) <.0001 Nonpermissive HVG 1.28 (1.05-1.55) .001 
Nonpermissive GVH 1.46 (1.25-1.71) <.0001 
aGVHD 3-4 Match  Match  Match  
Permissive 1.25 (0.99-1.59) .014 Core permissive 1.11 (0.83-1.48) .4 Core permissive 1.11 (0.83-1.48) .4 
Noncore permissive 1.36 (1.03-1.80) .005 Noncore permissive HVG 1.27 (0.87-1.86) .1 
Noncore permissive GVH 1.42 (1.03-1.96) .005 
Nonpermissive 1.48 (1.16-1.90) <.0001 Nonpermissive 1.48 (1.16-1.90) <.0001 Nonpermissive HVG 1.52 (1.11-2.09) <.001 
Nonpermissive GVH 1.46 (1.11-1.92) <.001 
NRM Match  Match  Match  
Permissive 1.12 (0.94-1.33) .09 Core permissive 1.09 (0.89-1.34) .3 Core permissive 1.09 (0.89-1.34) .3 
Noncore permissive 1.11 (0.90-1.37) .2 Noncore permissive HVG 1.21 (0.91-1.59) .08 
Noncore permissive GVH 1.05 (0.82-1.35) .6 
Nonpermissive 1.26 (1.05-1.50) .001 Nonpermissive 1.26 (1.05-1.50) .001 Nonpermissive HVG 1.17 (0.92-1.48) .09 
Nonpermissive GVH 1.31 (1.07-1.59) <.001 
Relapse Match  Match  Match  
Permissive 0.87 (0.77-0.99) .007 Core permissive 0.93 (0.80-1.08) .2 Core permissive 0.93 (0.80-1.08) .2 
Noncore permissive 0.83 (0.71-0.97) .003 Noncore permissive HVG 0.93 (0.75-1.15) .4 
Noncore permissive GVH 0.77 (0.63-0.94) <.001 
Nonpermissive 0.77 (0.67-0.88) <.0001 Nonpermissive 0.77 (0.67-0.88) <.0001 Nonpermissive HVG 0.83 (0.69-1.00) .010 
Nonpermissive GVH 0.73 (0.63-0.86) <.0001 

Multivariable models were adjusted for patient and donor age, sex (mis)matching, cytomegalovirus serostatus matching, HCT comorbidity score,22 Karnofsky performance score, disease at transplant, disease risk index,23 year of HCT, stem cell source, conditioning regimen and use of total-body irradiation, use of in vivo T-cell depletion, and GVHD prophylaxis regimen.

or Create an Account

Close Modal
Close Modal